Price to earnings forward of Orthofix Medical Inc. – NASDAQ:OFIX
The article provides the "Price to earnings forward" financial metric for Orthofix Medical Inc. (NASDAQ: OFIX). It references market data from ICE Data Services and FactSet, and notes that SEC filings are provided by Quartr. The content is presented in a financial data context.
Canaccord reiterates Orthofix Medical stock rating after CMS reversal
Canaccord Genuity reiterated a Buy rating and $18.00 price target on Orthofix Medical (NASDAQ:OFIX) shares following the Centers for Medicare & Medicaid Services’ (CMS) reversal of reimbursement changes for bone growth stimulators. The CMS's decision to rescind previously implemented reimbursement changes led Orthofix Medical to expect Medicare reimbursement to return to pre-May 18 levels, affecting its previously lowered financial outlook for 2026. This reversal also suggests the stock appears undervalued at current levels, with analysts predicting profitability and an EPS of $0.82 for the year.
Orthofix Medical stock surges on Medicare reimbursement reversal By Investing.com
Orthofix Medical Inc. shares surged 12% after Medicare reversed its changes to reimbursement rates for non-invasive bone growth stimulators. The Centers for Medicare & Medicaid Services withdrew modifications to billing requirements that had been implemented in May 2026, meaning reimbursement rates will return to prior levels. This reversal is significant for Orthofix as Medicare reimbursement directly impacts revenue from these products.
Orthofix Medical Inc. (OFIX) Sees 6.7% Pre-Market Increase
Orthofix Medical Inc. (OFIX) experienced a 6.7% pre-market surge, attributed to positive market sentiment ahead of the trading session and potential healthcare sector recovery. Despite the stock uptick, the company faces significant challenges in profitability and financial strength, evidenced by a GF Score™ of 58/100 and negative earnings. Insider activity shows a mixed picture, with net selling but also some buying during the last three months.
Barrington Raises Price Target on Orthofix Medical to $17 From $15, Keeps Outperform Rating
Barrington has increased its price target for Orthofix Medical Inc. (OFIX) to $17 from $15, while maintaining an "Outperform" rating on the stock. This adjustment comes as Orthofix Medical continues to present at healthcare conferences and announce expansions to its product portfolio. The company's stock shows a 5-day change of +17.10% and a year-to-date change of +20.14%.
Enterprise value to revenue forward of Orthofix Medical Inc. – NASDAQ:OFIX
The article focuses on the enterprise value to revenue forward metric for Orthofix Medical Inc. (NASDAQ: OFIX). It appears to be a financial data entry page from TradingView, providing an overview of the company's financial metrics. The content itself seems to be a placeholder or a very brief snapshot of this specific financial data point.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Orthofix
Faruqi & Faruqi, LLP is investigating potential claims against Orthofix Medical Inc. following a federal securities class action lawsuit. The investigation centers on allegations that Orthofix issued false and misleading statements regarding its management team, leading to a significant stock price drop after the September 12, 2023, disclosure of the termination of key executives for code of conduct violations. Investors who suffered losses exceeding $75,000 between October 11, 2022, and September 12, 2023, are encouraged to contact the firm by the October 21, 2024, lead plaintiff deadline.
Orthofix Medical (OFIX) Among the Best Small-Cap Growth Stocks To Buy Now
Orthofix Medical Inc. (NASDAQ: OFIX) is highlighted as one of the best small-cap growth stocks to invest in, despite a recent 22% stock decline. Analysts remain bullish, forecasting over 54% upside. The medical device company reported strong revenue for fiscal Q1 2026, exceeding estimates, and provided positive full-year 2026 sales guidance.
Orthofix Medical (OFIX) Surges 10% After CMS Reversal on Bone Gr
Orthofix Medical (OFIX) saw its stock surge by approximately 10% in after-hours trading following the Centers for Medicare & Medicaid Services (CMS) rescinding an order that would have reclassified non-invasive bone growth stimulators. This reversal means the devices will continue to be processed and compensated under previous treatment standards, positively impacting the company's revenue and financial outlook. Despite the positive regulatory news, investors are advised to exercise caution due to the company's moderate GF Score, financial challenges, and significant insider selling.
Stocks to Watch: Seer, Orthofix Medical, Halozyme Therapeutics
This article identifies several stocks to watch, including Seer, Orthofix Medical, and Halozyme Therapeutics. The selections are likely based on recent news, financial performance, or market activity concerning these companies. Investors may consider these stocks for potential opportunities or risks.
Orthofix (OFIX) expects Medicare bone stimulator reimbursement to return to prior levels
Orthofix Medical Inc. (OFIX) expects Medicare reimbursement rates for its non-invasive bone growth stimulators to revert to prior levels after the Centers for Medicare & Medicaid Services (CMS) withdrew billing changes. CMS initially altered billing rules following the FDA's reclassification of these devices from Class III to Class II but later issued revised guidance to process and pay claims consistent with pre-reclassification treatment. Orthofix anticipates average Medicare reimbursement for HCPCS codes E0747, E0748, and E0760 will return to rates effective before May 18, 2026, though actual outcomes depend on implementation, claim volumes, and payer behavior.
Orthofix Medical (Nasdaq:OFIX) - Stock Analysis
Orthofix Medical (OFIX) is trading significantly below its estimated fair value and analysts project a substantial price increase. Despite currently being unprofitable, the company has released new medical devices and provided earnings guidance for upcoming years. Recent updates focus on CMS reimbursement changes impacting non-invasive bone growth stimulators and shifts in analyst price targets.
Orthofix Medical, Inc. Actuals & Estimates (NASDAQ:OFIX)
This article provides an overview of Orthofix Medical Inc. (OFIX) stock, including its current price, market capitalization, and analyst forecasts. It also details financial actuals and estimates, discusses past earnings reports, and confirms that the company does not pay dividends.
Orthofix Medical, Inc. Actuals & Estimates (FWB:OM2)
This article provides an overview of Orthofix Medical, Inc. (FWB:OM2) financial actuals and analyst estimates. It details the company's stock ticker, forecast price range, historical highs and lows, earnings reports, revenue, net income, dividend policy, and employee count. Key financial figures for the last quarter, including earnings per share and revenue, are also highlighted.
OFIX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Orthofix Medical Inc. (OFIX) stock, including analyst price targets, historical performance, and financial data. Analysts have a maximum 1-year price estimate of $18.00 and a minimum of $12.00. The article also covers the company's current stock price, market capitalization, earnings, revenue, and upcoming earnings report date on August 11, 2026.
Orthofix Medical Inc (OFIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
Orthofix Medical Inc (OFIX) currently has a price momentum score of 6.36 and is trading between a resistance level of $10.34 and a support level of $8.22, suggesting suitability for range-bound swing trading. Technical indicators show predominantly sell signals, with 3 sell signals and 0 buy signals, and moving averages from MA5 to MA200 all indicate sell signals for the stock. This analysis suggests a bearish outlook based on the given technical data.
Orthofix Medical Inc. (OFIX) exec sells 3,670 shares for tax withholding
Orthofix Medical Inc. executive Aviva McPherron sold 3,670 shares of common stock at $9.38 per share to cover tax withholding obligations related to restricted stock unit settlement. This transaction was mandated by a pre-approved "sell-to-cover" program, leaving McPherron with no discretion over the sale. Following the sale, McPherron still directly holds 66,330 shares, including restricted stock units and shares from the company's Stock Purchase Plan.
Orthofix Medical Inc (OFIX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Orthofix Medical Inc (OFIX), noting its current valuation score of 7.97, ranking 119 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -6.34 and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Orthofix Medical Inc (OFIX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Orthofix Medical Inc (OFIX), detailing its current earnings forecast score of 8.00 and ranking in the Healthcare Equipment & Supplies industry. It includes analyst ratings, target prices, expected revenue, and EPS for upcoming periods. The consensus among five analysts is a "Buy" trend for the stock.
Orthofix Medical Inc (OFIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Orthofix Medical Inc (OFIX) across various business segments and geographical regions. As of April 6, 2025, Spinal Implants represent the largest revenue contributor, followed by Bone Growth Therapies. The United States accounts for the significant majority of the company's regional revenue.
Orthofix Medical Inc (OFIX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Orthofix Medical Inc (OFIX) focusing on its dividend and stock split history. It notes that no dividend data or stock split events are recorded for the company. The page also presents current stock performance metrics and links to other financial analysis tools.
OFIX Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events for Orthofix Medical (OFIX) stock, highlighting legal investigations into management for fiduciary breaches by firms like Halper Sadeh LLC and Purcell & Lefkowitz. It also covers the company's lowered full-year outlook due to Medicare changes and Q1 2026 earnings, which beat expectations despite the challenges. The latest news also notes Orthofix Medical's discontinuation of the President position in Global Spine Solutions.
Understanding Momentum Shifts in (OFIX)
The article provides an AI-driven analysis of Orthofix Medical Inc. (OFIX), indicating weak sentiment across all time horizons and supporting a short bias for the stock. It identifies elevated downside risk and offers institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also details multi-timeframe signal strengths for near-term, mid-term, and long-term periods.
Orthofix (OFIX) director Michael Finegan receives 20,721 deferred units
Orthofix Medical Inc. director Michael Finegan was awarded 20,721 deferred stock units, which will vest entirely on the first anniversary of the grant date, provided he continues his service with the company. These units represent a right to receive one share of common stock each, to be delivered within 45 days after his service ends. Following this award, Finegan's total holdings in Orthofix now amount to 81,617 shares and deferred stock units.
Director at Orthofix (OFIX) awarded 14,965 deferred stock units
Orthofix Medical Inc. director Vickie L. Capps was granted 14,965 deferred stock units as compensation, which will vest fully on the first anniversary of the grant date, subject to her continued board service. This award increases her total direct and deferred holdings in Orthofix to 43,300 shares and units. The vested units convert to common stock within 45 days after her service with the company ends, according to the recent Form 4 SEC filing.
Orthofix (OFIX) awards director Michael Paolucci 14,965 deferred stock units
Orthofix Medical Inc. director Michael E. Paolucci was granted 14,965 deferred stock units. These units, which vest in full on the first anniversary of the grant date subject to his continued service, will convert into common stock within 45 days after his service with the company ends. Following this award, Paolucci directly holds a total of 102,727 units and shares.
Orthofix Medical (OFIX) director granted 14,965 deferred stock units as equity award
Orthofix Medical director John B. Henneman III received an equity award of 14,965 deferred stock units, which vest within one year conditioned on his continued service. This grant, valued at $0.00 per unit, is a routine non-cash compensation award, not an open-market transaction. Following this award, Henneman's direct holdings now total 105,774 shares and units, including previously reported deferred stock units.
[Form 4] Orthofix Medical Inc. Insider Trading Activity
Orthofix Medical Inc. Director Shweta Maniar reported the acquisition of 14,965 deferred stock units as equity compensation, with a grant price of $0.00. These units vest fully on the first anniversary of the grant date, contingent on her continued service. Following this transaction, Maniar holds a total of 69,038 deferred stock units.
Orthofix Medical (OFIX) awards 14,965 deferred stock units to director Burris
Orthofix Medical Inc. director Wayne Burris was granted 14,965 deferred stock units of common stock, which vest fully on the first anniversary of the grant date, contingent on his continued service. These units, received at no cost, will convert into Orthofix common stock within 45 days after his service terminates. Following this grant, Burris's direct holdings in deferred stock units total 65,504, including previously reported units.
Director equity grant at Orthofix Medical (OFIX) totals 14,965 units
Orthofix Medical Inc. director Alan Lee Bazaar received an equity award of 14,965 deferred stock units. These units will vest on the first anniversary of the grant date, provided he continues board service, and will convert to common stock within 45 days after his service ends. Following this grant, Bazaar's total holdings in Orthofix, including previous deferred stock units and shares from the Stock Purchase Plan, amount to 65,489 shares and units.
Orthofix (NASDAQ: OFIX) adds 1.25M shares to employee stock plan
Orthofix Medical Inc. announced that its shareholders approved an amendment to its Second Amended and Restated Stock Purchase Plan, adding 1,250,000 common shares for issuance. This amendment was one of several items approved at the 2026 Annual Meeting of Shareholders, where a quorum was present, and director nominees received substantial support. The changes aim to further align employee and shareholder interests without altering other plan terms.
Orthofix Medical Inc. Common Stock (DE) (OFIX) Stock Price Today & Analysis
This article provides an analysis of Orthofix Medical Inc. (OFIX) stock, including its current price, fundamental financials, and corporate actions. It details the company's segments in orthopedic and spine solutions and offers a guide on how to buy OFIX stock through the Gotrade app. The piece also addresses frequently asked questions regarding minimum investment, dividends, and market hours.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Orthofix
Faruqi & Faruqi, LLP is investigating potential claims against Orthofix Medical Inc. (NASDAQ: OFIX) and encourages investors who suffered losses exceeding $75,000 to contact them. The investigation follows a federal securities class action filed against the company concerning allegedly false and misleading statements about its management team, which led to a significant stock price drop. Investors have until October 21, 2024, to seek the role of lead plaintiff.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Orthofix
Faruqi & Faruqi, LLP is investigating potential claims against Orthofix Medical Inc. (NASDAQ: OFIX) on behalf of investors who suffered losses exceeding $75,000 between October 11, 2022, and September 12, 2023. The investigation follows a significant drop in Orthofix's stock price after the company announced the termination of its CEO, CFO, and Chief Legal Officer for violating code of conduct requirements. Investors are reminded of the October 21, 2024 deadline to seek the role of lead plaintiff in the federal securities class action.
Juniper investment, 10% owner, sells $2.59m Orthofix medical shares By Investing.com
Juniper Investment Company, a 10% owner of Orthofix Medical Inc. (NASDAQ:OFIX), sold 242,000 shares of common stock for approximately $2.59 million on May 22, 2026. This transaction occurred as OFIX stock trades near its 52-week low. The sale follows Orthofix Medical's first-quarter 2026 earnings beat but an updated financial outlook for 2026 due to anticipated Medicare reimbursement declines for bone growth stimulators.
What's Driving the Activist Pressure on Orthofix Medical (OFIX)
Orthofix Medical (OFIX) is facing renewed activist investor pressure, reminiscent of a 2009 campaign, due to its declining stock performance, strategic shifts like discontinuing M6 product lines, and insider selling. Despite a "Hold" consensus from analysts and a potential 44% upside to the average price target of $20.00, the company grapples with merger integration challenges, unprofitability, and legal issues. The article suggests a "Hold" rating for existing shareholders, advising new investors to await clearer signs of operational improvement and stability.
Juniper investment, 10% owner, sells $2.59m Orthofix medical shares By Investing.com
Juniper Investment Company, a 10% owner of Orthofix Medical Inc. (NASDAQ:OFIX), sold 242,000 shares of common stock for approximately $2.59 million on May 22, 2026, at a weighted average price of $10.6992 per share. This transaction occurred as OFIX stock trades near its 52-week low, though InvestingPro analysis suggests it might be undervalued. Orthofix Medical also recently reported Q1 2026 earnings that surpassed analyst expectations but revised its full-year financial guidance downward due to changes in Medicare reimbursement for bone growth stimulators, leading analysts to lower price targets.
Juniper-managed funds trim Orthofix (OFIX) stake with 242K-share sale
Funds managed by Juniper Investment Company, LLC, including Juniper Targeted Opportunity Fund, L.P., sold 242,000 shares of Orthofix Medical Inc. (OFIX) common stock. The sale occurred at a weighted average price of $10.6992 per share, though Juniper-managed funds retain a significant stake in Orthofix totaling over 4.4 million shares across various entities. Juniper and its managing members disclaim beneficial ownership beyond their pecuniary interest.
Orthofix Medical Inc reports results for the quarter ended March 31 - Earnings Summary
Orthofix Medical Inc. has released its earnings summary for the quarter that concluded on March 31. The report, provided by Refinitiv, gives an overview of the company's financial performance during this period. Further details of the report can be accessed by signing in or creating a free account on the platform.
Juniper group discloses 11% Orthofix Medical (OFIX) stake and new share buys
An investor group advised by Juniper Investment Company has disclosed a collective beneficial ownership of approximately 11% in Orthofix Medical Inc. (OFIX), totaling 4,442,543 common shares. This stake includes recent open-market purchases of 657,926 shares by Juniper Targeted Opportunity Fund between February 13, 2026, and May 22, 2026, for about $7.41 million. Alexis P. Michas and John A. Bartholdson are identified as managing members and beneficial owners within the group.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Orthofix Medical Inc. (NASDAQ: OFIX)
Purcell & Lefkowitz LLP has launched an investigation into Orthofix Medical Inc. (NASDAQ: OFIX) to determine if the company's directors breached their fiduciary duties. The firm is offering assistance to shareholders interested in learning more about their rights and options regarding these corporate actions. Shareholders can contact the firm via their website, email, or telephone for a free consultation.
CCORF Maintains Orthofix Medical(OFIX.US) With Buy Rating, Maintains Target Price $20
CCORF has reiterated its Buy rating for Orthofix Medical (OFIX.US) and maintained its target price of $20. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Canaccord cuts Orthofix Medical stock price target on reimbursement headwinds
Canaccord has lowered its price target for Orthofix Medical (NASDAQ:OFIX) shares from $20 to $18, while maintaining a Buy rating. The adjustment is due to new reimbursement challenges, particularly affecting the Bone Growth Stimulation segment, which now projects only 1% growth compared to the company's expected 2-3% market growth. Despite exceeding Q1 2026 earnings and revenue forecasts, the company revised its full-year 2026 financial guidance downwards and does not anticipate achieving positive free cash flow, mainly because Medicare reimbursement changes are expected to decrease by around 10% for certain codes.
Barrington Adjusts Price Target on Orthofix Medical to $15 From $17, Maintains Outperform Rating
Barrington Research has adjusted its price target for Orthofix Medical (NASDAQ: OFIX) shares to $15, down from the previous $17. Despite the reduction in the price target, the firm has maintained an Outperform rating on the medical device company's stock. This update reflects Barrington's continued positive outlook on Orthofix Medical's performance potential.
Stifel cuts Orthofix Medical stock price target on reimbursement hit
Stifel lowered its price target for Orthofix Medical Inc. to $15 from $18 due to reduced reimbursement rates for bone growth stimulators, following a 10% cut by CMS. Orthofix Medical has revised its 2026 revenue and adjusted EBITDA guidance downwards and no longer expects positive free cash flow this year. Despite these challenges, analysts predict the company will be profitable in 2026, with an EPS forecast of $0.96.
Orthofix Medical updates 2026 outlook after CMS Medicare cuts for bone growth stimulators
Orthofix Medical has revised its 2026 financial guidance downward following CMS Medicare reimbursement cuts for non-invasive bone growth stimulators, which are expected to reduce Medicare rates by approximately 10%. The company now projects net sales between $838M–$848M and non-GAAP adjusted EBITDA of $90M–$93M. Orthofix also suspended its three-year financial targets and does not anticipate positive free cash flow in 2026 due to these actions.
Medicare cuts push Orthofix (NASDAQ: OFIX) to lower 2026 outlook and scrap 3-year goals
Orthofix Medical Inc. (OFIX) has lowered its 2026 financial outlook and withdrawn its three-year targets due to anticipated Medicare reimbursement cuts for non-invasive bone growth stimulators. Following an FDA reclassification and CMS billing updates effective May 18, 2026, the company expects a 10% decline in average Medicare reimbursement for key codes. This change is projected to result in 2026 net sales of $838–$848 million, non-GAAP adjusted EBITDA of $90–$93 million, and no positive free cash flow for the year.
Orthofix lowers outlook on Medicare changes to bone growth stimulators
Orthofix Medical (OFIX) stock dropped significantly after the company lowered its full-year outlook. The revision was attributed to upcoming Medicare reimbursement changes affecting its non-invasive bone growth stimulators. As a result, the MedTech firm has adjusted its net sales projections.
Orthofix Medical Inc stock (US6875231068): spine specialist in focus after recent setbacks and restructuring push
Orthofix Medical Inc. is undergoing a significant transformation amidst leadership changes, restructuring efforts, and softer demand in its core markets. The company, a specialist in musculoskeletal care with a focus on spine and orthopedics, reported weaker financial results for Q4 and full-year 2024. Investors are closely monitoring the success and pace of its turnaround strategy, which relies on niche product differentiation, innovation, and navigating a complex regulatory and competitive landscape.
Orthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. announced its participation in two upcoming investor conferences. The company will have a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and will hold 1x1 meetings at the Truist Securities MedTech Conference on June 16, 2026. Interested parties can access the webcast of the Goldman Sachs chat on the Orthofix Investor Relations website.
